去势抵抗性前列腺癌转移灶中18F-氟二氢睾酮半定量摄取指标的可重复性与再现性:一项前瞻性多中心研究
这项前瞻性多中心研究对27例转移性去势抵抗性前列腺癌患者连续两天进行两次18F-FDHT PET/CT扫描,评估半定量摄取指标的可重复性与观察者间再现性。结果显示SUV指标可重复性最佳,RC为21.3%–24.6%,观察者间再现性高(ICC>0.98)。
要点
- 27例患者共140个18F-FDHT高摄取区域纳入分析。
- SUV指标可重复性最佳,RC为21.3%(SUVpeak)至24.6%(SUVmax)。
- 所有指标观察者间再现性高,ICC>0.98。
核心结论
- 18F-FDHT PET/CT得出的摄取指标显示高可重复性和观察者间再现性。
研究设计与样本
- 前瞻性多中心研究,纳入转移性去势抵抗性前列腺癌患者,连续两天进行两次(测试/复测)18F-FDHT PET/CT扫描。
- 两名独立阅片者评估所有检查,记录32个预设解剖区域中各区域摄取最高病灶的SUV、雄激素受体阳性肿瘤体积和总病灶摄取。
主要发现
- 共纳入27例患者,140个18F-FDHT高摄取区域。
- SUV指标(SUVmax、SUVmean、SUVpeak)可重复性最佳,彼此间无显著差异;测试与复测扫描间所有SUV指标相关性强(R2≥0.92;ICC≥0.97)。
- SUV指标的RC范围为21.3%(SUVpeak)至24.6%(SUVmax)。
- 雄激素受体阳性肿瘤体积和TLU的测试与复测高度相关(R2和ICC≥0.97),但变异性显著高于SUV(RC>46.4%)。
- 前列腺特异性抗原水平、Gleason评分、体重和年龄不影响可重复性,总注射活度、摄取测量时间或两次扫描间摄取时间差异也不影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18F-fluorodihydrotestosterone (18F-FDHT) is a radiolabeled analog of the androgen receptor's primary ligand that is currently being credentialed as a biomarker for prognosis, response, and pharmacodynamic effects of new therapeutics. As part of the biomarker qualification process, we prospectively assessed its reproducibility and repeatability in men with metastatic castration-resistant prostate cancer. Methods: We conducted a prospective multiinstitutional study of metastatic castration-resistant prostate cancer patients undergoing 2 (test/retest) 18F-FDHT PET/CT scans on 2 consecutive days. Two independent readers evaluated all examinations and recorded SUVs, androgen receptor-positive tumor volumes, and total lesion uptake for the most avid lesion detected in each of 32 predefined anatomic regions. The relative absolute difference and reproducibility coefficient (RC) of each metric were calculated between the test and retest scans. Linear regression analyses, intraclass correlation coefficients (ICCs), and Bland-Altman plots were used to evaluate repeatability of 18F-FDHT metrics. The coefficient of variation and ICC were used to assess interobserver reproducibility. Results: Twenty-seven patients with 140 18F-FDHT-avid regions were included. The best repeatability among 18F-FDHT uptake metrics was found for SUV metrics (SUVmax, SUVmean, and SUVpeak), with no significant differences in repeatability among them. Correlations between the test and retest scans were strong for all SUV metrics (R2 ≥ 0.92; ICC ≥ 0.97). The RCs of the SUV metrics ranged from 21.3% (SUVpeak) to 24.6% (SUVmax). The test and retest androgen receptor-positive tumor volumes and TLU, respectively, were highly correlated (R2 and ICC ≥ 0.97), although variability was significantly higher than that for SUV (RCs > 46.4%). The prostate-specific antigen levels, Gleason score, weight, and age did not affect repeatability, nor did total injected activity, uptake measurement time, or differences in uptake time between the 2 scans. Including the most avid lesion per patient, the 5 most avid lesions per patient, only lesions 4.2 mL or more, only lesions with an SUV of 4 g/mL or more, or normalizing of SUV to area under the parent plasma activity concentration-time curve did not significantly affect repeatability. All metrics showed high interobserver reproducibility (ICC > 0.98; coefficient of variation < 0.2%-10.8%). Conclusion: Uptake metrics derived from 18F-FDHT PET/CT show high repeatability and interobserver reproducibility.
引用
- Vargas HA, Kramer GM, Scott AM, et al. Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. J Nucl Med. 2018. PMID: 29626121. doi:10.2967/jnumed.117.206490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。